BioMarin Pharmaceutical Inc. (BMRN) Stock Forecast
BMRN analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.32 / 5 from 28 analysts
- Price target
- $91.59 average of analyst targets
- Upside to target
- +67.5% from the latest close
- Next earnings
- October 26, 2026 EPS estimate $1.13
- 52-week range
- $49.67 – $70.24
BMRN analyst ratings
28 analystsNumber of analysts at each rating.
BMRN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BMRN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.79 | −$0.48 | $1.48 | $0.12 | +557.1% | 16 |
| Current fiscal year (2026) | $4.46 | $3.33 | $5.07 | $3.15 | +41.5% | 19 |
| Next fiscal year (2027) | $6.44 | $4.14 | $7.35 | $4.46 | +44.5% | 18 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BMRN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.02B | $1.00B | $1.05B | +32.0% | 23 |
| Current fiscal year (2026) | $3.91B | $3.87B | $4.03B | +21.4% | 26 |
| Next fiscal year (2027) | $4.48B | $4.22B | $4.71B | +14.5% | 25 |
BMRN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BMRN revenue: reported and forecast
BMRN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.49 | $1.37 | $1.34 | $1.04 | $0.79 | −47.1% | 0 up · 5 down |
| Current fiscal year (2026) | $4.94 | $5.03 | $5.02 | $4.70 | $4.46 | −9.7% | 1 up · 5 down |
| Next fiscal year (2027) | $6.43 | $6.63 | $6.63 | $6.64 | $6.44 | +0.1% | 4 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BMRN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BMRN beat in 7 of 12.
What analysts expect from BMRN
28 analysts cover BioMarin Pharmaceutical; their consensus rating is buy (4.32 on a 1–5 scale, where 5 is a strong buy). The average price target is $91.59, 67.5% above the latest close of $54.68. Analysts expect earnings of $4.46 per share for 2026, +41.5% from a year earlier. For 2027 the average estimate is $6.44 per share on revenue of $4.5 billion. BioMarin Pharmaceutical beat the EPS estimate in 7 of the last 12 quarters.
Related: BMRN income statement, BMRN key metrics, BMRN chart. See the BMRN stock overview for the latest quote and news.
BMRN forecast FAQ
What is BioMarin Pharmaceutical's price target?
The average analyst price target for BioMarin Pharmaceutical is $91.59, 67.5% above the latest close of $54.68.
Is BioMarin Pharmaceutical a buy, hold or sell?
Of 28 analysts covering BioMarin Pharmaceutical, 16 rate it a strong buy, 5 a buy, 7 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is BioMarin Pharmaceutical's EPS forecast?
Analysts forecast $4.46 per share for 2026 (range $3.33 to $5.07); for 2027 the estimate is $6.44.
What is BioMarin Pharmaceutical's revenue forecast?
The average revenue estimate for 2026 is $3.9 billion, growth of 21.4%; for 2027 it is $4.5 billion.
When does BioMarin Pharmaceutical report earnings?
BioMarin Pharmaceutical is expected to report results for the quarter ending September 30, 2026 on October 26, 2026 after the market closes; the EPS estimate is $1.13.
Does BioMarin Pharmaceutical usually beat earnings estimates?
BioMarin Pharmaceutical reported EPS at or above the analyst estimate in 7 of the last 12 quarters.